Table 2.

ORs for the association between obesity and risk of overall, low-grade, and high-grade prostate cancer in the REDUCE study

	Overall cancer^b			Low-grade cancer^b Gleason (≤6)			High-grade cancer^b Gleason (≥7)
	Cases	OR^a (95% CI)	P	Cases	OR^a (95% CI)	P	Cases	OR^a (95% CI)	P
All men (N = 6,427)
Crude analysis	1,448 (23%)	0.84 (0.72–0.98)	0.022	1,008 (16%)	0.74 (0.62–0.89)	0.001	440 (7%)	1.08 (0.86–1.37)	0.50
Adjusted analysis^a		0.92 (0.79–1.07)	0.28		0.79 (0.65–0.94)	0.01		1.28 (1.01–1.63)	0.04
Placebo arm (N = 3,270)
Crude analysis	823 (25%)	0.84 (0.69–1.03)	0.10	594 (18%)	0.79 (0.62–0.99)	0.04	229 (7%)	0.99 (0.71–1.39)	0.98
Adjusted analysis^a		0.92 (0.75–1.13)	0.45		0.84 (0.66–1.06)	0.15		1.18 (0.84–1.66)	0.35
Dutasteride arm (N = 3,157)
Crude analysis	635 (20%)	0.83 (0.66–1.04)	0.11	414 (13%)	0.67 (0.50–0.89)	0.006	221 (7%)	1.18 (0.85–1.65)	0.32
Adjusted analysis^a		0.91 (0.73–1.15)	0.44		0.71 (0.53–0.95)	0.02		1.41 (1.00–1.98)	0.05

↵^aAdjusted for age, race, PSA, DRE findings, TRUS volume, and study treatment arm.
↵^bReferents were nonobese men (BMI <30 kg/m²) and no cancer.